(NP (NP (NN Retinoid) (NN differentiation) (NN therapy)) (PP (IN in) (NP (JJ promyelocytic) (NN leukemia))) (. .))
(S (NP-SBJ (NP (JJ Acute) (JJ promyelocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN APL)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ specific) (NN type)) (PP (IN of) (NP (JJ acute) (JJ myeloid) (NN leukemia))) (VP (VBN characterized) (NP (-NONE- *)) (PP (IN by) (NP-LGS-COOD (NP (NP (DT the) (NN morphology)) (PP (IN of) (NP (DT the) (NN blast) (NNS cells)))) (, ,) (NP (DT a) (JJ specific) (NN t-LRB-15;17-RRB-) (NN translocation)) (, ,) (CC and) (NP (NP (NNS risks)) (PP (IN of) (NP (JJ definite) (NN coagulopathy))))))))) (. .))
(S (ADVP-TMP (RB Recently)) (NP-SBJ-72 (DT this) (NN leukemia)) (VP (VBD was) (VP (ADVP (RB further)) (VBN characterized) (NP (-NONE- *-72)) (PP (IN by) (NP-LGS-COOD (NP (NP (DT an) (JJ exquisite) (NN sensitivity)) (PP (TO to) (NP (NP (JJ all-trans) (JJ retinoic) (NN acid) (POS 's)) (NN differentiation) (NN effect)))) (CC and) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (DT a) (NN fusion) (NN gene)) (VP (VBG altering) (NP-COOD (NP (NP (DT the) (NN gene)) (PP (IN of) (NP (NN RARalpha)))) (CC and) (NP (DT a) (JJ novel) (NN gene) (NN PML))))))))))) (. .))
(S (NP-SBJ (NP (ADJP (FW In) (FW vivo)) (NN differentiation) (NN therapy)) (PP (IN with) (NP (NNS retinoids))) (PP (IN in) (NP (NN APL) (NNS patients)))) (VP (VBZ follows) (NP (NP (JJ strict) (NNS guidelines)) (ADJP (JJ related) (PP (CC both) (TO to) (NP-COOD (NP (DT the) (NN APL) (NN cell)) (CC and) (NP (NP (DT the) (NN biodisposal)) (PP (IN of) (NP (JJ all-trans) (JJ retinoic) (NN acid))))))))) (. .))
